Within one year three of 25 patients with rheumatoid arthritis treated with azathioprine 100 mg daily developed the following adverse reactions less than two weeks after starting treatment: patient one showed fever with chills, rash, and severe liver function abnormalities suggestive of cholestasis; the second patient had fever, nausea, diarrhoea, and moderately raised liver enzymes; the third patient showed very high fever and severe chills. In two patients the drug was rechallenged, with more rapidly arising and more severe symptoms. In one case raised liver enzymes persisted until seven months after discontinuation of azathioprine. Hypersensitivity reactions and hepatotoxicity of azathioprine are discussed.
the drug.' To our knowledge the combination of liver function abnormalities with fever, chills, and rash has been reported before in only two patients. 2 Recently, we observed in one year three patients with rheumatoid arthritis (RA) treated with 100 mg azathioprine daily who developed fever and chills with liver function abnormalities (two patients) and rash (one patient).
The clinical picture of these three patients is described and allergic adverse reactions to azathioprine and the hepatotoxicity of the drug are discussed. 176 U/I (normal <40 U/1). Two days later the clinical situation worsened and he was admitted to hospital. Apart from severe dermatitis of his hands with vesicles and pustules and a moderately active RA, physical examination on admission was normal. Laboratory findings were as follows: ESR 93 mm/h, haemoglobin 120 g/l, leucocytes (including eosinophils) and platelets normal. Alkaline phosphatase 810 U/1, yglutamyltransferase 295 U/1, serum asparate aminotransferase (AST) 127 Hepatotoxicity associated with azathioprine can develop between two weeks and 33 months after starting treatment,6 8 possibly depending on the origin of hepatotoxicity. The mechanisms of azathioprine hepatotoxicity may be threefold-namely (a) allergic (with simultaneous systemic allergic symptoms); (b) direct hepatotoxic (exact mechanism unknown12); (c) blockade of the liver blood outflow at the junction of sinusoids and centrilobular veins, causing peliosis hepatitis.'3 Davis et al have suggested that the imidazole moiety of azathioprine causes the allergic symptoms and the 6-mercaptopurine moiety the liver injury.'0 Histologically, the picture of azathioprine hepatotoxicity consists of intrahepatic cholestasis with variable degrees of liver cell necrosis and slight (peri)portal inflammatory reaction. Biochemically, abnormal liver function tests are found, ranging between a cholestatic pattern and increase of transaminase.6 12 Azathioprine hepatotoxicity is mostly a reversible process, but normalisation of liver enzymes can take several months,8 as shown in patient 1. For different reasons it seems unlikely that diclofenac had a role in the production of liver dysfunctions in patient 1. Firstly, he had already used that drug for several years without side effects. Secondly, liver function returned to normal (very slowly) while treatment with diclofenac was continuing. Thirdly, the pattern of liver enzyme increase (cholestatic) is unusual for diclofenac hepatotoxicity. 4 Reintroduction of a smaller dose of azathioprine in dose related hepatotoxicity seems justified,9 but rechallenge of azathioprine when there is a suspicion of hypersensitivity can be dangerous and lead to life threatening shock. 1' '7 In patient 2 the reintroduction of azathioprine was not our intention but happened accidentally. Retrospectively, the first period of fever and malaise in patient 3 was not recognised as azathioprine toxicity. If there is a compelling reason for reintroducing azathioprine it must be done under very careful clinical observation.'7 For completeness we point out that the spectrum of azathioprine hypersensitivity can include more symptoms. '8 In summary, with these three case reports of azathioprine hypersensitivity in patients with RA we draw attention to this serious complication and recommend that liver function tests are carried out two weeks after starting azathioprine and thereafter every one to two months.
Addendum
Very recently we saw a new case of severe azathioprine hypersensitivity in a patient whose clinical picture was similar to that of patient 1. The patient, a 27 year old man who had had destructive seropositive RA since 1983, was admitted to hospital because of fever (39-2°C), chills, nausea, cough, and purpura on his legs. He had taken azathioprine 100 mg for 12 We are grateful to Dr M Kruiisen (Ziekenhuis Ziekenzorg, Enschede, The Netherlands) for allowing us to study his patients, and we wish to thank Mrs Marion Janssen for her excellent secretarial help.
